BIOMAT Database Logo BIOMAT Database Logo

Foscarnet for suppression of human immunodeficiency virus replication. 1994

C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Department of Pharmacy Practice, University of Minnesota, Minneapolis.

The effect of foscarnet against human immunodeficiency virus (HIV) was evaluated in nine HIV-infected individuals; six completed 28 days of induction therapy. The overall mean increase in CD4+ lymphocytes was 64 cells per mm3. The mean decline in the HIV antigen concentration was 108 pg/ml (P = 0.03), and suppression was related to systemic foscarnet exposure by a maximum-effect pharmacodynamic model.

UI MeSH Term Description Entries
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001499 Bayes Theorem A theorem in probability theory named for Thomas Bayes (1702-1761). In epidemiology, it is used to obtain the probability of disease in a group of people with some characteristic on the basis of the overall rate of that disease and of the likelihood of that characteristic in healthy and diseased individuals. The most familiar application is in clinical decision analysis where it is used for estimating the probability of a particular diagnosis given the appearance of some symptoms or test result. Bayesian Analysis,Bayesian Estimation,Bayesian Forecast,Bayesian Method,Bayesian Prediction,Analysis, Bayesian,Bayesian Approach,Approach, Bayesian,Approachs, Bayesian,Bayesian Approachs,Estimation, Bayesian,Forecast, Bayesian,Method, Bayesian,Prediction, Bayesian,Theorem, Bayes
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015488 HIV Antigens Antigens associated with specific proteins of the human adult T-cell immunodeficiency virus (HIV); also called HTLV-III-associated and lymphadenopathy-associated virus (LAV) antigens. AIDS Antigens,HIV-Associated Antigens,HTLV-III Antigens,HTLV-III-LAV Antigens,LAV Antigens,Lymphadenopathy-Associated Antigens,T-Lymphotropic Virus Type III Antigens, Human,HIV Associated Antigens,HTLV III Antigens,HTLV III LAV Antigens,Lymphadenopathy Associated Antigens,T Lymphotropic Virus Type III Antigens, Human,Antigens, AIDS,Antigens, HIV,Antigens, HIV Associated,Antigens, HIV-Associated,Antigens, HTLV III,Antigens, HTLV-III,Antigens, HTLV-III-LAV,Antigens, LAV,Antigens, Lymphadenopathy Associated,Antigens, Lymphadenopathy-Associated,Associated Antigens, HIV,Associated Antigens, Lymphadenopathy,III Antigens, HTLV

Related Publications

C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Foscarnet decreases human immunodeficiency virus RNA.
July 1995, The Journal of infectious diseases,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Suppression of human immunodeficiency virus replication during acute measles.
April 2002, The Journal of infectious diseases,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Suppression of human immunodeficiency virus type 1 replication by human herpesvirus-6.
October 1990, The Journal of infectious diseases,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
In vitro suppression of human immunodeficiency virus type 1 replication by measles virus.
July 2005, Journal of virology,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Suppression of simian immunodeficiency virus replication by human immunodeficiency virus type 1 trans-dominant negative rev mutants.
August 1995, Journal of virology,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
HLA compatibility requirements for CD8(+)-T-cell-mediated suppression of human immunodeficiency virus replication.
December 1998, Journal of virology,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.
September 1995, Virology,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Regulation of human immunodeficiency virus replication.
January 1991, Annual review of microbiology,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Suppression of human immunodeficiency virus replication in human brain tissue by nucleoside reverse transcriptase inhibitors.
April 2004, Journal of neurovirology,
C V Fletcher, and A C Collier, and F S Rhame, and D Bennett, and M F Para, and C C Beatty, and C E Jones, and H H Balfour
Fcgamma receptor-mediated suppression of human immunodeficiency virus type 1 replication in primary human macrophages.
April 2003, Journal of virology,
Copied contents to your clipboard!